Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in SJS and TEN
NCT06474078Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Aug 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tofacitinib oral solution in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Complete Skin Healing Time. Started Aug 2022; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on NCT06474078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474078.